Novo Nordisk A/S (NVO) shares jumped Friday after the company's Wegovy weight loss pill posted impressive early prescription numbers. According to IQVIA data cited by Reuters, the newly launched pill hit 3,071 U.S. prescriptions in just its first four days on the market. That's the kind of debut that gets Wall Street's attention, and investors responded by pushing the stock up over 7%.

The Numbers Behind The Hype

So what makes this pill worth watching? The clinical data is actually pretty compelling. When combined with a reduced-calorie diet and exercise, the Wegovy pill showed an average weight loss of about 17% compared to roughly 3% for placebo. That 16.6% figure assumes everyone stayed on treatment throughout the study.

The weight loss pill received FDA approval back in December 2025, and now the market is doing what it always does: watching early sales numbers like a hawk to gauge whether this thing has real commercial legs.

U.K. Gives Green Light to Higher Dose

Friday also brought regulatory news from across the pond. The U.K.'s Medicines and Healthcare products Regulatory Agency approved a maximum dose of up to 7.2mg per week of Wegovy for weight management. This is a bigger deal than it might sound.

Novo Nordisk submitted its application to the FDA for this higher 7.2mg semaglutide injection dose back in November 2025. Thanks to the Commissioner's National Priority Voucher expedited program, the company expects a decision within one to two months after the FDA accepted the filing.

Meanwhile, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on the higher dose, with Novo Nordisk expecting a final EU regulatory decision sometime in the first quarter of 2026.

How The Higher Dose Actually Works

Here's where it gets a bit technical, but stay with me because this matters. The MHRA approval covers adult patients with obesity who have a Body Mass Index of 30 kg/m² or higher. The higher dose is administered as three separate 2.4mg injections for weight management, combined with diet and exercise.

Importantly, this approval doesn't apply to overweight patients with a BMI under 30 kg/m² or to patients using Wegovy to reduce their risk of serious heart problems. It's specifically for obesity treatment.

Patients starting Wegovy begin with a 0.25mg weekly dose. Healthcare professionals then guide patients through gradual increases every four weeks until reaching the standard 2.4mg per week maintenance dose. If needed, doctors can escalate to the 7.2mg weekly dose after a minimum of four weeks on 2.4mg.

The Practical Details

For patients prescribed the 7.2mg dose, the reality is they'll need to administer three separate 2.4mg injections one after another on the same day. The injections can go in the same body area but must be at least 5cm apart. Patients need to change needles between each dose and might need multiple pens to complete their weekly regimen.

Each pen contains four 2.4mg doses, so patients shouldn't toss it until they've used all four. Partially used pens should be refrigerated with the needle removed. Once all four doses are gone, the pen gets disposed of safely per the prescriber's instructions.

The Clinical Trial Results

Back in November 2025, Novo Nordisk shared data from the STEP UP phase 3b trial comparing the 7.2mg dose against the standard 2.4mg dose and placebo for weight management in adults with obesity. The results showed that the higher dose helped obese patients lose an average of 21% of their body weight. That's a meaningful jump from the 17% seen with the standard pill dose.

These kinds of results explain why the market is paying such close attention to this launch. Weight loss drugs have become one of the hottest pharmaceutical categories, and Novo Nordisk is clearly betting big on expanding its Wegovy franchise with both pill formulations and higher doses.

NVO Price Action: Novo Nordisk shares were up 7.20% at $61.23 at the time of publication on Friday.